О так называемой «воспалительной кардиомиопатии»
Аннотация
В статье на основании современных данных литературы анализируется патогенез вирусного поражения миокарда, в результате которого развивается цепь патологических нарушений, названных термином «вирусный миокардит». Убедительно показана роль вирусов в разнообразных клеточных и молекулярных изменениях сердечной мышцы.
Дана критическая оценка предложенному рядом зарубежных исследователей термину «воспалительная кардиомиопатия», оставляя за дефиницией «кардиомиопатия» лишь заболевания неясной или неизвестной этиологии.
Об авторах
С. Р. Мравян
Московский областной научно-исследовательский клинический институт им. М.Ф.Владимирского, Москва
Россия
Тел.: (095)284-53-33
Россия
Тел.: (095)284-53-33
М. А. Гуревич
Московский областной научно-исследовательский клинический институт им. М.Ф.Владимирского, Москва
Россия
Тел.: (095)284-53-33
Россия
Тел.: (095)284-53-33
Список литературы
1. McCarthy RE III, Boehmer JP, Hruban RH, et al. Long-term outcome of fulminant myocarditis as compared with acute (nonfulminant) myocarditis. N Engl J Med 2000; 342: 690-5.
2. D’Ambrosio A., Patti G, Manzoli A, et al. The fate of acute myocarditis between spontaneous improvement and evolution to dilated cardiomyopathy: a review. Heart 2001; 85: 499-504.
3. Why HJ, Meany BT, Richardson PJ, et al. Clinical and prognostic significance of detection of enteroviral RNA in the myocardium of patients with myocarditis or dilated cardiomyopathy. Circulation 1994; 14: 2582-9.
4. Terasaki F, Okabe M, Hayashi T, et al. Myocardial inflammatory cell infiltrates in cases of dilated cardiomyopathy: light microscopic, immunohistohemical, and virological analyses of myocardium speciments obtained by partial left ventriculectomy. J Card Surg 1999; 14: 141-6.
5. Richardson P, McKenna W, Bristow M, et al. Report of the 1995 World Hearth Organisation/International Society and Federation of Cardiology Task Force on the Definition and Classification of the cardiomyopathies. Circulation 1996; 93: 841-2.
6. Noutsias M, Pauschinger M, Schultheiss H-P, Köhl U. Advances in the immunohistological diagnosis of inflammatory cardiomyopathy. Eur Heart J 2002; 4(Suppl.II): 154-62.
7. Атрощенко Е.С. Кардиомиопатия инфекционного генеза: воспалительные и аутоиммунные механизмы формирования сердечной недостаточности. Сердце 2003; 6: 297-9.
8. Calabrese F, Thiene G. Myocarditis and inflammatory cardiomyopathy: microbiological and molecular biological aspects. Cardiovasc Res 2003; 60: 11-25.
9. Bergelson J, Cunningham J, Droguett G, et al. Isolation of a common receptor for coxsackie B viruses and adenoviruses 2 and
10. Science 1997; 275: 1320-3.
11. Tomko R, Xu R, Philipson L. HCAR and MCAR: the human and mouse cellular receptor for subgroup C adenoviruses and group B coxsackieviruses. Proc Natl Acad Sci USA.1997; 94: 3352-6.
12. Fechner H, Haack A, Wang H, et al. Expression of coxsackieadenovirus-receptor and α v intergin does not correlate with adenovector targeting in vivo indicating anatomical vector barriers. Gene Ther 1999; 6: 1520-35.
13. Noutsias F, Fechner H, Jonge Hd, et al. Human coxsackie-adenovirus-receptor is co-localized with intergins α v β3 and αv β5 on the cardiomyocyte sarcolemma and upregulated in dilated cardiomyopathy; implications for cardiotropic viral infections. Circulation 2001; 104: 275-80.
14. Poller W, Fechner H, Noutsias M, et al. The molecular basis of cardiotropic viral infections. Europ Heart J 2002; 4(Suppl.II): 118-30.
15. Noutsias M, Seeberg B, Schultheiss H, et al. Expression of cell adhesion molecules in dilated cardiomyopathy: evidence for endothelial activation in inflammatory cardiomyopathy. Circulation 1999; 99: 2124-31.
16. Fechner H, Haack A, Wang H, et al. Expression of coxsackieadenovirus-receptor and α v intergin does not correlate with adenovector targeting in vivoindicating anatomical vector barriers. Gene Ther 1999; 6: 1520-35.
17. Pickles R, McCarty D, Matsui H, et al. Limited entry of adenivirus vectors into well-differentiated airway epithelium is responsible for unefficient gene transfer. J Virol 1998; 72: 6014-23.
18. Carlquist JF, Menlove RL, Murray MB, et al. HLA class II (DR and DQ) antigen associations in idiopathic dilated cardiomyopathy. Validation study and meta-analysis of published HLA association studies. Circulation 1999; 83: 515-22.
19. Klingel K, Rieger P, Mall G, et al. Visualisation of enteroviral replication in myocardial tissue by ultrastructural in situ hubridisation: identification of target cells and cytopathic effects. Lab Invest 1998; 78: 1227-37.
20. Kandolf R, Ameis D, Kirschner P, et al. In situ detection of enteroviral genomes in myocardial cells by nucleic acid hybridization: An approach to the diagnosis of viral heart disease. Proc Natl Acad Sci USA 1987; 84: 6272-6.
21. Klingel AK, Sauter M, Bock CT, et al. Parvovirus B19-infected myocardial and endothelial cells: a cause of disturbed coronary microcirculation? Z Kardiol 2002; 91: 144-7.
22. Pauschinger M, Doerner A, Kuehl U, et al. Enterioviral RNA replication in the myocardium of patients with left ventricular dysfunction and clinically suspected myocarditis. Circulation 1999; 99: 889-95.
23. Turesson C. Endothelial expression of MHC class II molecules in autoimmune disease. Curr Pharm Dis 2004; 10: 129-43.
24. Huber SA, Job LP. Cellular immune mechanisms in coxsackievirus group B, type 3 induced myocarditis in Balb/C mice. Adv Exp Med Biol 1983; 161: 491-508.
25. Köhl U, Noutsias M, Seeberg B, Schultheiss H-P. Immunological evidence for a chronic intramyocardial inflammatory process in dilated cardiomyopathy. Heart 1996; 75: 295-300.
26. Springer TA. Adhesion receptors of the immune system. Nature 1990; 346: 425-34.
27. Caforio ALP, Grazzini M, Mann JM, et al. Identification of the alpha and beta myosin heavy chain isoforms as major autoantigens in dilated cardiomyopathy. Circulation 1992; 85: 1734-42.
28. Wang Z, Liao Y, Dong J, et al. Clinical significance and pathogenic role of anti-cardiac myosin autoantibody in dilated cardiomyopathy. Chin Med J 2003; 116: 499-502.
29. Milton AD, Fabre JW. Massive induction of clones type class I and class II major histocompatibility complex antigents in rejecting cardiac allografts in the heart. J Exp Med 1985; 161: 98-112.
30. Young JDE. Killing of target cells by lymphocytes: A mechanistic view. Physiol Rev 1989; 69: 250-314.
31. Young LHY, Klavinskis LS, Oldstone MBA. In vivo expression of perforin by DB8+ lymphocytes during an acute viral infection. J Exp Med 1989; 169: 2159-71.
32. Seko Y, Ymazaki T, Shinkai Y. Cellular and molecular basis for the immunopatholigy of the myocardial cell damage involved in acute viral myocaditis with special reference to dilated cardiomyopathy. Jpn Circ J 1992; 56: 1062-72.
33. Yigzhen Y, Dingding X, Yangang S. Expression of perforin and Fas lagand in infiltrating cells in murine myocardium with acute myocarditis caused by Coxsackievirus B3. XIX Congr of the Europ Society of Card. Eur Heart J 1997; 18(Ref): 2949.
34. Griffiths GEM, Voorhees JJ, Nickoloff BJ. Characterization of intracellular adhesion molecuke-1 and HLA-DR expression in normal and inflammeted skin: Modulation by recombinant gamma interferon and tumor necrosis factor. J Am Acad Dermatol 1989; 20: 617-29.
35. Wojnicz R, Kozielska E, Szczurek K, et al. HLA, ICAM-1 and VCAM-1 molecules in the endomyocardial biopsy specimens - patients with clinically suspected myocarditis. XIX Congr of the Europ Society of Card. Eur Heart J 1997; 18(Ref): 3467.
36. Takemoto M, Kusachi S, Urabe N, et al. Auto-antibody against adenine nucleotide translocator in dilated cardiomyopathy and myocarditis. Jpn Circ J 1993; 57; 1150-8.
37. Schultheis H-P. The mitochondrium as antigen in inflammatory heаrt disease. Eur Heart J 1987; 8: 139-42.
38. Wolf PG, Kuhl V, Schultheiss HP. Laminin distribution and autoantibodies to laminin in dilated cardiomyopathy and myocarditis. Am Heart J 1989; 117: 1306-9.
39. Herzum M, Maisch B. Humoral and cellular immune reactions to the myocardium in myocarditis. Herz; 17: 91-8.
40. Pauschinger M, Chandrasekharan K, Schultheiss HP. Myocardial remodeling in viral heart disease: possible interactions between inflammatory mediators and MMP-TIMP system. Heart Fail Rev 2004; 9: 21-31.
41. Pauschinger M, Chandrasekharan K, Li J, et al. Inflammation and extracellular matrix protein metabolism: two sides of myocardial remodeling. Eur Heart J 2002; 4(Suppl.I): I49-53.
42. The WHO/ISFC Task Force. Report of the WHO/ISFC Task Force on the definition and classification of cardiomyopathies. Вrit Heart J 1980; 44: 672-3.
43. The WHO/ISFC Task Force. Report of the 1995 WHO/ISFC Task Force on the definition and classification of cardiomyopathies. Cirulation 1996; 93: 841-2.
44. Sangiorgi M. Clinical and epidemiological aspects of cardiomyopathies: a critical review of current knowledge. Eur J Int Med 2003; 14: 5-17.
45. Znoiko O, Yuschuk N. Invasive and non-invasive monitoring of hepatitis C virus-induced liver fibrosis: alternatives or complements. Curr Pharm Biotech 2003; 4: 195-209.
46. Caforio AL, Baboonian C, MacKenna WJ. Postviral autoimmune heart disease: fact or fiction? Eur Heart J 1997; 18: 1051-5.
47. Hahn EA, Hartz VL, Moon TE, et al. The Myocarditis Treatment Trial: Design, methods and patient enrolment. Eur Heart J 1995; 16: 162-7.
Рецензия
Для цитирования:
Мравян С.Р., Гуревич М.А. О так называемой «воспалительной кардиомиопатии». Кардиоваскулярная терапия и профилактика. 2005;4(3, ч.II):88-93.
For citation:
Mravyan S.R., Gurevich M.A. About so called “inflammatory cardiomyopathy”. Cardiovascular Therapy and Prevention. 2005;4(3, ч.II):88-93. (In Russ.)
Просмотров:
708
Послать статью по эл. почте 
